Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment With the Combination of Epirubicin and Paclitaxel Alone or Together With Capecitabine as First Line Treatment in Metastatic Breast Cancer. A Multicenter, Randomized Phase III Study

NCT01433614 is registered in ClinicalTrials.gov with Thomas Hatschek as lead sponsor.

NCT NCT01433614
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01433614 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment With the Combination of Epirubicin and Paclitaxel Alone or Together With Capecitabine as First Line Treatment in Metastatic Breast Cancer. A Multicenter, Randomized Phase III Study
Lead sponsor
Thomas Hatschek
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2002
Completion date
December 31, 2013
Enrollment
304 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer